**Table 1**. Characteristics of included trials (N=2113).

|  |  |  |  |
| --- | --- | --- | --- |
| **Trial characteristic1** | **All trials, N=2113** | **Trials registered in the EUCTR (with or without ClinicalTrials.gov), n=432** | **Trials registered only at ClinicalTrials.gov, n=1681** |
| Country |  |  |  |
| Denmark | 1019 (48.2) | 255 (59) | 764 (45.4) |
| Finland | 231 (10.9) | 56 (13) | 175 (10.4) |
| Iceland | 10 (0.5) | 3 (0.7) | 7 (0.4) |
| Norway | 328 (15.5) | 33 (7.6) | 295 (17.5) |
| Sweden | 525 (24.8) | 85 (19.7) | 440 (26.2) |
| Registry2 |  |  |  |
| Registered in the EUCTR | 432 (20.4) | 432 (100) | N/A |
| Registered at ClinicalTrials.gov | 2008 (95.0) | 327 (75.7) | 1681 (100) |
| Intervention type3 |  |  |  |
| Medicinal product | 675 (31.9) | 432 (100) | 244 (14.5) |
| Not medicinal product | 1438 (68.1) | N/A | 1437 (85.5) |
| Design (missing, n=3) |  |  |  |
| Randomized controlled | 1516 (71.7) | 305 (70.6) | 1211 (72) |
| Non-randomized | 594 (28.1) | 127 (29.4) | 467 (27.8) |
| Masking (missing, n=8) |  |  |  |
| Open label | 1157 (54.8) | 245 (56.7) | 912 (54.3) |
| Any masking | 948 (44.9) | 187 (43.3) | 761 (45.3) |
| Sponsor type4 |  |  |  |
| Industry or mixed | 158 (7.5) | 22 (5.1) | 136 (8.1) |
| Only non-industry | 1955 (92.5) | 410 (94.9) | 1545 (91.9) |
| Phase |  |  |  |
| I | 65 (3.1) | 12 (2.8) | 53 (3.2) |
| I-II | 30 (1.4) | 11 (2.5) | 19 (1.1) |
| II | 197 (9.3) | 150 (34.7) | 47 (2.8) |
| II-III | 21 (1.0) | 8 (1.9) | 13 (0.8) |
| III | 61 (2.9) | 39 (9) | 22 (1.3) |
| IV | 240 (11.4) | 196 (45.4) | 44 (2.6) |
| Not given | 1499 (70.9) | 16 (3.7) | 1483 (88.2) |
| Multicentric |  |  |  |
| Yes | 526 (24.9) | 136 (31.5) | 390 (23.2) |
| No (monocentric) | 1587 (75.1) | 296 (68.5) | 1291 (76.8) |
| Enrollment (actual or anticipated; missing, n=1) |  |  |  |
| 1 - 100 | 1464 (69.3) | 13 (3) | 120 (7.1) |
| 100 - 500 | 515 (24.4) | 319 (73.8) | 1145 (68.1) |
| > 500 | 133 (6.3) | 100 (23.1) | 415 (24.7) |
| Completion year (actual or anticipated) |  |  |  |
| 2016 | 521 (24.7) | 113 (26.2) | 408 (24.3) |
| 2017 | 528 (25.0) | 130 (30.1) | 398 (23.7) |
| 2018 | 557 (26.4) | 92 (21.3) | 465 (27.7) |
| 2019 | 507 (24.0) | 97 (22.5) | 410 (24.4) |
| Status |  |  |  |
| Completed | 1675 (79.3) | 349 (80.8) | 1326 (78.9) |
| Terminated | 150 (7.1) | 62 (14.4) | 88 (5.2) |
| Unknown status | 288 (13.6) | 21 (4.9) | 267 (15.9) |

Percentages may exceed 100 because of rounding. 1Total count may differ between categories because of missing data (number missing shown if >0). 2Subcategories are not mutually exclusive. 3Medicinal product trials included all EUCTR trials, and ClinicalTrials.gov trials with the labels drug, biological, genetic, or combination product; non-medicinal product trials included ClinicalTrials.gov trials with the labels behavioral, device, diagnostic test, dietary supplement, procedure, radiation, or other. 4Among lead or collaborating sponsors.